Matthias Ulrich Kassack

17PUBLICATIONS
43CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsBiologically active moleculesCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Feb 13, 2025
Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties.

Daniel Stopper, Lukas Biermann, Paris R Watson

|Nov 27, 2024
Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.

Fabian Fischer, Julian Schliehe-Diecks, Jia-Wey Tu

|Nov 27, 2024
YAK577 Attenuates Cardiac Remodeling and Fibrosis in Isoproterenol-Infused Heart Failure Mice by Downregulating MMP12.

Hongyan Zhou, Hae Jin Kee, Le Wan

|Oct 16, 2024
Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer.

Lukas M Bollmann, Friedrich Lange, Alexandra Hamacher

|Aug 10, 2024
The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells.

Laura S Pradel, Yu-Lin Ho, Holger Gohlke

|Jun 27, 2024
Novel Histone Deacetylase (HDAC) Inhibitor Induces Apoptosis and Suppresses Invasion via E-Cadherin Upregulation in Pancreatic Ductal Adenocarcinoma (PDAC).

Katja Schiedlauske, Alina Deipenbrock, Marc Pflieger

Pageof 3

Frequent Collaborators

7 joint publications

Thomas Kurz

3 joint publications

Finn K Hansen

3 joint publications

Holger Gohlke

3 joint publications

Wolfgang A Schulz